Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy
Yujue Wang, Sixue Liu, Zhentao Yang, Alain P. Algazi, Shirley H. Lomeli, Yan Wang, Megan Othus, Aayoung Hong, Xiaoyan Wang, Chris E. Randolph, Alexis M. Jones, Marcus Bosenberg, Stephanie D. Byrum, Alan J. Tackett, Henry Lopez, Clayton Yates, David B. Solit, Antoni Ribas, Marco Piva, Gatien Moriceau, Roger S. Lo
Topics & Concepts
Cancer researchMelanomaNeuroblastoma RAS viral oncogene homologMAPK/ERK pathwayTrametinibCytotoxic T cellImmunotherapyDabrafenibImmune checkpointImmune systemMedicineCD8ImmunologyTargeted therapyBiologyVemurafenibColorectal cancerMetastatic melanomaKinaseCancerInternal medicineIn vitroCell biologyKRASBiochemistryCancer Immunotherapy and BiomarkersCAR-T cell therapy researchImmunotherapy and Immune Responses